We provide a comprehensive analysis of the potential of targeting C3/C3aR signaling as a novel GBM therapy, including the application of small-molecule antagonists, synergistic effects with radiotherapy, and the prospects for biomarker development based on liquid biopsy. This evidence concerns the gene C3 and glioblastoma.